Mechanistic Approaches of Internalization, Subcellular Trafficking, and Cytotoxicity of Nanoparticles for Targeting the Small Intestine

Asadullah Madni, Sadia Rehman, Humaira Sultan, Muhammad Muzamil Khan, Faiz Ahmad, M. Rafi Raza, Nadia Rai, and Farzana Parveen

Received 24 July 2020; accepted 5 November 2020; published online 22 November 2020

Abstract. Targeting the small intestine employing nanotechnology has proved to be a more effective way for site-specific drug delivery. The drug targeting to the small intestine can be achieved via nanoparticles for its optimum bioavailability within the systemic circulation. The small intestine is a remarkable candidate for localized drug delivery. The intestine has its unique properties. It has a less harsh environment than the stomach, provides comparatively more retention time, and possesses a greater surface area than other parts of the gastrointestinal tract. This review focuses on elaborating the intestinal barriers and approaches to overcome these barriers for internalizing nanoparticles and adopting different cellular trafficking pathways. We have discussed various factors that contribute to nanocarriers’ cellular uptake, including their surface chemistry, surface morphology, and functionalization of nanoparticles. Furthermore, the fate of nanoparticles after their uptake at cellular and subcellular levels is also briefly explained. Finally, we have delineated the strategies that are adopted to determine the cytotoxicity of nanoparticles.

KEY WORDS: targeted drug delivery; nanocarriers; small intestine; intestinal barriers; cellular trafficking; cytotoxicity.

INTRODUCTION

The oral route is always considered the appropriate and reliable pathway for delivering therapeutic agents due to increased patient compliance, particularly in chronic illness. It ensures convenience, facilitates self-administration, and offers excellent flexibility in dosage regimen as the highly sterile conditions are not required for oral products, their manufacture leading to a decline in production costs (1). Moreover, the oral route seems to have interesting physiological reasons as the surface area (300–400 m) of the gastrointestinal tract (GIT) is extensive for drug absorption through absorptive epithelial cells (2–6).

Despite the numerous advantages of oral delivery, it also possesses some drawbacks such as drug requires crossing manifold compartments of the human body before it reaches the systemic circulation, which is a challenging task (7). Furthermore, after ingestion, the drug faces the harsh acidic pH of the stomach before it arrives at the small intestine via the duodenum, which is said to be the central enzymatic digestion machinery of the human body (8). One of the most promising approaches to overcome the obstacles mentioned earlier of oral drug delivery is nanomedicine use.

Nanomedicines can be defined as either nanoscale (< 100 nm) therapeutic agents or imaging agents that result in systematic enhancement, shielding, specific targeting, controlled release, or reduced drug-induced cytotoxicity (9). The significant clinically used nanomedicines consist of liposomal, polymer-based, protein-based, silica, iron oxide, and gold nanoparticle (NP) (10). The bioavailability of orally delivered drugs is also enhanced by nanocarriers (11,12). Nanoparticles own numerous benefits in oral drug delivery; subsequently they present a large surface area for interactions with the gastrointestinal tract and might be altered in different ways in order to handle the barricades related to oral delivery. The size, shape, and surface chemistry of nanoparticles can significantly impact cellular uptake and treatment (13).

The vital intention of drug delivery based on nanotechnology targets the specific organs, tissues, and cells. Therefore, precise targeting of nanocarriers across the cell membrane is of primary importance (14). Thus, to achieve a more effective drug delivery mode, it needs to thoroughly understand the formulation of an optimized nanomedicine that can target the small intestine. If the intestine is targeted, it will help prevent drug degradation and enhance the small intestine absorption rate that highly improves the impact of
orally administered pharmaceuticals. Although by adopting
this route, the nanocarriers would more efficiently survive
through a healthy environment of GIT but to reach the
bloodstream, it has to be overcome intestinal barriers of the
small intestine. The internalization of nanoparticles can be
achieved by crossing intestinal obstacles such as the mucus
layer, the epithelial layer, and tight junctions. The physical
and chemical characteristics of nanoparticles also affect their
internalization. After their cellular uptake at the cellular and
subcellular levels, the fate of these particles is an extensive
study (15,16). For obtaining an optimized nanodrug delivery
system, cellular-induced cytotoxic response should also be
adequately studied (17).

This review article allows understanding the uptake
pathways adopted by the nanoparticles for internalization
and briefly discusses the barriers and the ways they adapt to
restrict the theoretically estimated delivery of nanoparticles
and the various approaches adopted by the researchers to
overcome these obstacles. The effect of surface chemistry of
nanoparticle is quite complicated on their cellular uptake.
This discussion would give brief information on the delivery
of nanoparticles to the targeted cells and even their interaction
with cellular organelles.

INTESTINAL BARRIERS

The most challenging obstacle of the human body for
nanoparticles to reach systemic circulation is to overcome the
intestinal barriers that include intestinal mucus, epithelial
cells, cellular organelles, and narrow junctions between the
cells. The villi are considered the main body of the digestive
tract’s various structures, enhancing the intestinal absorptive
surface area that is about 300–400 m² (18). The cells, for
example, enterocytes, microfold cells, and goblet cells, are
closely linked via tight junctions. The portions of the small
intestine are categorized as duodenum, jejunum, and ileum.
Naturally, it tends the absorption of nutrients.

Furthermore, villi are sheltered with mucus layers having
a variable thickness (2). The vital intention of nanotechnol-
ogy is targeting the specific organs, tissues, and even cells.
Therefore, precise targeting nanocarriers’ translocation across
the cell membrane is of primary importance (19). The drug
has to go through the following barriers

1. Mucus barrier
2. Tight junctions

The Mucus Barrier

The mucus layer is considered the primary physical
barrier that is usually a hydrogel-type structure which consists
of large glycoproteins that belong to the mucus family (20–
23). The goblet cells are responsible for mucus secretion,
which is also used to shield epithelial cells from the damage
caused by bacterial interactions or ingested food (24). In the
small intestine, goblet cells’ prominent mucin is MUC2 (25–
27). The small intestine consists of a 10- to 200-μm-thick
loosely adherent layer from the jejunum to the colon,
whereas the average production of mucus is “1” kg per day
in a healthy adult (28). The external loosely adhered layer is
comparatively less thick (20,29). The mucus layer is formed of
parallel and stacked sheets consisting of mucin molecules
present between the villi in the small intestine. The mucin
two–based sheet has its protein attached to the three
neighboring mucin cells building a hexagonal mesh structure
(27,30,31). In addition to mucin, many enzymes are also
present in the mucus layer that may pose a risk of degradation.

Though, despite being undisputedly extremely essential
for the human intestine shielding, it marks the primary barrier
to oral nanoparticles (32). Numerous nanomaterials get
immobilized by the mucus secretion and cannot reach the
epithelial cell layer. Notably, a functionalization with syn-
thetic resin polyethylene glycol (PEG) chains (33,34), the
mixture of anionic and cationic charges (35), and therefore
the application of self-nanoemulsifying drug delivery systems
(SNEDDS) are practical strategies to penetrate the mucosal
barrier (36). Anhydrous homogenous liquid mixtures
consisting of oil, surfactant, drug, and co-emulsifier having
the property of forming oil-in-water nanoemulsion are known
to be SNEDDS.

The mucus shows hydrophobic bonding with the nano-
particles and proteins (37). Moreover, the charge-bearing
mucin proteins hold the charged particles in the mucus layer
due to interaction between the charges (38). The charge
density of intestinal mucus mesh can rely upon the intestine’s
pH as well as ionic strength of intestinal contents and is also
affected by the chyme components within the small intestine.
The ionic strength and osmolality changes from hypotonic to
isotonic to hypertonic environment among diminutive spaces
in the gut subsequently taking nutrients (39).

A greater charge interaction occurs between nanoparti-
cles and mucus in the hypertonic environment and lesser in
hypotonic conditions (39). The particle–mucus interactions
are partially dependent on feeding state as denser and more
impenetrable mucus is related to postprandial levels of
calcium, lipids, and bile acids (40). It was observed that
dietary and biocompatible polymers could compress the
mucosa of the mouse colon, resulting in tightening the mucus
structure by up to 80% (41).

However, the outer loosely bounded layer causes the
immobilization of nanoparticles, proteins, or pathogens,
leading to the digestive tract’s rapid clearance by shedding
the mucus layer. However, small solute molecules, such as
nutrients, diffuse without hindrance through the mucus layer
(39). It was observed the surface of densely charged neutral
hydrophilic nanoparticle showed interactions with mucus to a
limited extent. In a study, Olmsted et al. perceived densely
charge-bearing particles but has neutral, hydrophilic surfaces
with mesh size almost about 100 nm (32,39,42). The mucus-
penetrating particles (MPPs) were prepared by considering
chemical properties of mucus with the capability of quick
transferring through the cervical mucus sheet (43,44); for
example, either the surface of MPP can be decorated by
functionalizing with low molecular weight PEG polymeric
chains or particles could be developed with fragile mucosal
interactions. The nanoparticles get trapped in the secreted
mucus by decreasing the PEG chain density.

Furthermore, the surface coverage has long PEG chains
incapable of entering the mucus mesh, almost certainly
because of the predilection among the stretched PEG chains
and the mucus layer. The mucus-penetrating particles were
observed to be bound to the epithelial layer’s surface whereas conventional particles were arrested within the external part of the mucus layer (44). A hydrophilic surface is characteristic of numerous soluble proteins that limited their interaction with mucus. For example, albumin protein has a negative charge; therefore, nanoparticles functionalized with serum albumin show repulsive and weak mucus interactions (45).

Theoretically, the concentrated and controlled delivery can be achieved by the nanoparticle-mucus binding. A feasible technique is used to transfer small and stable molecules in the enterocyte locality. In contrast, practically, the superficially bonded external mucus sheet and peptidases of the small intestine will be a substantial challenge to that strategy. Therefore, MPPs are considered a practical approach, but their worth after oral delivery is still under research (39,46).

Another strategy involves modifying nanoparticles with proteolytic enzymes such as papain, apparently enhancing the mucosal penetration by the breakdown of the mucoglycoprotein substructures (47). The most crucial barrier next to the mucus layer penetration is internalizing the foremost layer of epithelial cells. When the nanoparticles deliver at the apical pole of the epithelial layer, there arise dual opportunities for crossing the basal side. It involves paracellular transport that opens tight junctions, and transcellular delivery occurs among epithelial cells having no cellular uptake. For example, chitosan is considered a favorable polymer for achieving paracellular uptake, which can open tight junctions reversibly (48).

**Tight Junction**

The seal between the two attached epithelial cells that resist paracellular trafficking of small molecules such as water, ions, and solutes is known as a tight junction as shown in Fig. 1 (49,50). They are generally situated in a circle near the apical side of the cell. The separation of the basolateral and apical poles of the epithelial membrane is due to these junctions. Tight junctions are formed by branching strands which further consist of layers of transmembrane proteins having extracellular territories primarily that may be 27-membered claudin family and occludin (51).

Claudins have two different groups, including the barrier-forming group or the pore-creating group, which control the selective transport of small solute molecules through the epithelium. Moreover, they occur in different sets in variable tissues, and it is indicated that the proteins are liable in various tissues for the paracellular uptake including the small intestine (51). The loops are formed by extracellular parts of these proteins that get attached to conforming loops of neighboring cells, resulting in a seal among cells (52,53). And tricellulin is another type of tight junction protein that occurred between three adjacent cells (49).

Modulation of tight junction permeability has usually adopted by two forms of approaches: a seemingly less controlled tight junction modulation, making leaks that enable the passage of large molecules, and an additional controlled tight junction modulation. To create leaks, absorption enhancers or surface-active agents have been used. For example, fatty acids having medium chain length and their derivatives cause reversible leaks within narrow concentration intervals to occur between tight junctions (54,55). A controlled tight junction modulation appears to be an extra attractive approach than permeation enhancers to increase paracellular amide permeability. Still, the studies showed that it results in more narrow open pathways than absorption enhancers and seems therefore not to be a way to improve nanoparticle delivery.

It was observed by the scientist in animal studies that elevated concentrations of the peptides and also of insulin were required for significant modulation. It remains to be shown if this approach holds promise when scaled up to larger species (56), thus limiting the transport of nanoparticles (57,58).

**INTERNALIZATION OF NANOCARRIERS**

After the nanoparticles overcome the various cellular obstacles, the next challenge is the internalization of nanocarriers in the intestinal cell. Commonly, multiple pathways are adopted by the endothelial and epithelial cells including the uptake of the nanocarriers and interaction with cytosol and other cellular organelles leading to the fate or ejection of nanoparticles from the cell as shown in Fig. 2. Endocytosis is a process of uptake mechanism which is further characterized as pinocytosis and phagocytosis (59). The term endocytosis comprises the development of new vesicles from the cell membrane along with the introduction of proteins, lipids, and extracellular fluids whereas pinocytosis includes the internalization of liquid. At the same time, phagocytosis refers to the incorporation of solid particles (60,61).

The nanoparticles are transferred by intestinal cells through various pathways including:

1. Clathrin-mediated pathway
2. Caveolin-mediated pathway
3. Clathrin- and caveolin-independent pathway
4. Macropinocytosis (62)

Nature of the adopted endocytosis pathway is estimated by dimensions of the endocytic sac, the properties of the constituents, and the method used for the development of vesicles. The heterogeneity in the endocytic mechanism is responsible for the delivery of nanocarriers to various intracellular localities (63,64).

Clathrin-mediated uptake is occurred by specific receptor-ligand interaction and is also known as non-specific endocytosis. In this pathway, transmembrane receptors produce coated pits and components covered with cytosolic protein retracted to form vesicles that are probably assisted by GTPase dynamic protein. The dynamin protein encloses the neck of lately developed invagination (65). Hydrophobic interaction with the cell membrane is carried out by non-specific endocytosis pathway. The vesicles are 100–120 nm in size. The uncoated vesicles either resulted in the development of early endosomes or reprocessed to the surface of the plasma membrane. Then, these vesicles are converted to developed endosomes and then to lysosomes or multivesicular bodies. The small density lipoprotein is uptaken and transfers by this pathway. Clathrin-dependent endocytosis is also adopted by chitosan and PLGA nanoparticles (66).
Caveola-mediated endocytosis pathway is mainly regulated and comprises complex signaling pathways. In the interior plasma membrane, flask-shaped invaginations are formed known as caveolae which consist of glycosphingolipids and high cholesterol level. Caveolin-1 is a dimeric protein that gives shape and structure to the vesicles (67). GTP are dynamin mediated the splitting of caveolae from the membrane. The vesicle size is approximately 50–100 nm. The formation and deposition of caveolae are regulated by cavin-coated proteins besides with caveolins. The caveolae of endothelial cells take part in the trans-endothelial mechanism, which is under investigation for the transfer of nanomaterials to subendothelial tissues. The neutral pH of caveosomes avoids the interaction between caveosomes and the hydrolytic environment. The site-specific delivery of therapeutic material is explored via the uptake of caveosomes by the Golgi apparatus and endoplasmic reticulum (8,68,69).

Clathrin- and caveola-independent endocytosis mechanism is not mediated by receptors or induced stimuli. The internalization and vesicle formation is independent of coat proteins, but actin and its related protein are significant for the development of vesicles. After the delivery of a therapeutic agent to the endosome, they reach the Golgi apparatus or may be recycled by the plasma membrane. In vaccine development, the polyplexes of self-branched and disaccharide relieved nanoparticles composed of chitosan oligomer have been discovered to transport DNA for site-specific delivery and in vivo vascular imaging (8).

The macropinocytosis is autonomous of the action of either receptor or molecular ligand for their activation. The protrusions are formed at the outer part of the plasma membrane under the action of actin. These protrusions show further merging with the cell membrane and result in the synthesis of macropinosomes and help in the delivery of bulks of extracellular fluid. The macropinosomes are > 1 μm in size, typically with irregular shape (70). In comparison, the macropinosomes are seemed to be affected by cytoplasmic pH (71). They either get fused with the compartment of lysosomes or may reutilize their content; therefore, macropinosomes also represent a fate like endosomes. The
fragments of an apoptotic cell, bacteria, and viruses are generally ingested by this pathway (72).

Factors Affecting the Internalization of Nanoparticles

Although nanoparticles are commonly indicated for their enhanced therapeutic and diagnostic effects, they need modification in their properties to achieve better internalization. Moreover, the intestine environment, along with intercellular trafficking and organelle interaction, also affects internalization. The researchers have made several attempts to obtain the best optimal results to target the site of action and minimize the side effects of therapeutic ingredients. These modifications help them in cellular internalization and crossing the barriers and show a high impact on future health care and improved clinical benefits. Their physical and chemical properties most commonly influence the internalization of nanoparticles. These properties include size, surface charge, shape, rigidity, and functionalization of these particles with receptors (73).

The nature of charge present on the nanoparticles has a high impact on the internalization through intestinal epithelial cells. For instance, Mei et al. modified the nanoparticles with a cationic surfactant that create a positive charge, which ensured enhanced retention time at the cellular membrane. The uptake mechanism was boosted, resulting in the high bioavailability of therapeutic agents (74). Similarly, the cancerous cells impart a negative charge due to the overexpression of phospholipids that negatively affect normal cells.

The studies showed that nanoparticles’ stiffness and softness could alter the cellular uptake and their targeting and biodistribution. It was also suggested that rate of cellular uptake is directly proportional to their rigidity since they show latent receptor-mediated diffusion and comparatively more contact surface area with the plasma membrane (75,76). Though nanoparticles’ rigidity can be determined by the relationship among stress and strain given by Young’s modulus, even it is challenging to measure the particles of micro- or nanosize (Yi and Gao 2017).

As far as the size of the nanoparticles is considered, it is a vital feature for trafficking through the cellular compartments. In the endocytosis pathway, the cellular membrane enfolded the particles, so the required considerations for membrane folding the radius of curvature cannot form insignificant, failing to capture the infinitely small particles (77,78). Moreover, the optimum size for nanoparticles necessary for the effective endocytosis pathway is observed by cell nature (79–83).

It is reported that as the nanoparticle comes in contact with the cell membrane, the contact angle showed a significant effect on endocytosis (84,85). Therefore, the different shapes of nanoparticles lead to diverse angles and consequently affect the internalization of nanoparticles (86,87). But, the internalization of spherical nanoparticles is not dependent on their contact angle due to their symmetrical shape. Moreover, engulfment failure occurs when the contact angle and points of attachment to the cell membrane enhance by diminutive axis, i.e., right angle to the membrane (88). Likewise, the polymeric nanoparticles had shown both a high rate of attachment and less internalization rate in comparison to spheroidal and oblate ellipsoidal nanoparticles having a small contact angle having major axis 0.35–2.0 μm and minor axis 0.2–2.0 μm (89).

Some of the important features of the factors are summarized past studies in Table I, showing the researchers’ better options to develop suitable nano formulation.

Functionalization to Target Receptors

The advance research is additionally based on enhancing the rate of transcytosis by functionalizing nanoparticles with various proteins. Such as, in Calu-3 airway epithelial cells, a bioconjugation of polymeric NPs with Fc part of immunoglobulin ‘G’ a constant portion of ‘IgG’ successfully enhances the rate of transcytosis (113). A study observed 16HBE cells uptake having 60 nm in size and positively charged polysaccharide nanoparticles significantly enhance endocytosis after cholesterol depletion. To follow, filipin is supplemented to the medium of cells subjected to nanoparticles, which substantially lower the rate of exocytosis (114).

The transcytosis could be significantly increased in Caco-2 cells by 2-fold via functionalization. The particles were modified with Fc fragments that quickly attached to the neonatal Fc receptor in the epithelium of the intestine. It was observed that Fc-bonded nanoparticles passed over the intestinal barrier in both in vitro experiments by using human epithelium and in vivo in mice (who also express FcRn), resulting in enhancing concentration levels in different organs of the body (115).

The decoration with folic acid to target the folate receptors is considered an attractive opportunity for oral drug delivery. In Caco-2 cells, PLGANPs functionalized with folic acid vastly augmented transcytosis proficiency and are utilized to increase oral bioavailability (116). Subsequently, the cellular uptake of macromolecules is triggered by the interaction of receptors on the cell surface and the ligands (opsonins). Examples of some significant receptors used in phagocytosis include Fc receptor family for IgG (FcγRI, FcγRIIA, and FcγRIIA), the complement receptors (CR1, CR3, and CR4), and α5β1 integrin (117). For example, Fowler and his coworkers revealed that nanoparticles containing insulin targeting the FcRn receptor achieved a prolonged hypoglycemic response in mice when administered orally at a clinical dose. Correspondingly, a bioconjugation with vitamin B12 having a size range of 50-nm or 100-nm nanoparticles not only enhances the trafficking by 3-fold to 7-fold but also results in the adjustment of the pathway and prohibited the nanoparticle transport to lysosomes (118). Roger et al. studied the modification of particles with folic acid to target the folate receptors. It was hypothesized that the trafficking of nanoparticles and their cellular uptake could be additionally enhanced by targeting the folate receptors present on the epithelial cells of the intestine (116).

NANOPARTICLE-INTRACELLULAR ORGANELLE INTERACTION

The intestinal cells consist of a diversity of intracellular organelles and compartments. The nanoparticle interaction with cellular systems and their localization, recognition, and quantification in intestinal cells are of significant prominence to comprehend the impact of physicochemical factors that might stimulate the potential interaction with a definite cell type and their responses (119). Once the nanoparticle enters
### Table I. Factors Affecting the Internalization of Nanoparticles

| Surface properties | Effective uptake | Description | Example | Diagrammatic illustration |
|--------------------|------------------|-------------|---------|--------------------------|
| **Surface charge** | Charged nanocarriers were observed more effectively than neutral nanoparticles [74]. | Improved charge-dependent binding to the outer surface of the plasma membrane. Positive charge exhibited more affinity as the plasma membrane has overall negative charge with few positive domains resulting in patchy arrangement [13, 90-96]. | Positively charged nanoparticles of zinc oxide showed enhanced selective cytotoxic potential against cancerous cells compared to negatively charged zinc oxide nanoparticles coated with polyacrylic acid [97, 98]. |
| **Rigidity of nanoparticles** | Stiff particles were easily wrapped by the cell membrane as compared to soft nanoparticles whereas [99]. | The stiffness of nanomaterials can also be related to particles' shape, leading to different wrapping levels as more bending energy is required by the cell membrane to engulf the spread form [100, 101]. | It was reported that solid nano-capsules were completely engulfed by the cellular membrane and require less adhesion energy than the fluid vesicular nanoparticles [102]. |
| **Size of nanoparticles** | Particles having a smaller diameter internalize more rapidly than the particle with a relatively larger diameter. But ultra-small nanoparticles do not always follow the set the trend; there are some size limitations among these particles [103-105]. | The smaller the particles lesser the time required by them to cross the cellular barriers and reach their fate, excluding the size of ultra-small nanoparticles ranging from 2-3 nm [106]. On the other hand, the nanoparticles of size ranging from 60-70 nm adopted lower kinetics and more time for internalization [107]. | The alveolar macrophages engulf particles of about 36 μm range while peripheral blood mononuclear cells seem to ingest particles of about 0.31-1 μm range [108]. |
| **Shape of nanoparticles** | The particles having elongated and sharp shape showed rapid internalization more than the flatter shape [103]. | The particles have oblate spheroid shape adhere to the plasma cell membrane like a 'backpack' because of their flatter morphology and reduce the entrance [109-111]. | Polystyrene (PS) nanoparticles having elliptical disk possessed a small contact angle. Therefore, they get attached to the cell membrane perpendicularly along its axis and was further engulfed by the wrapper of the symmetrical membrane [112]. |
into the cell, the evaluation of their distribution in different cellular compartments including mitochondria, cytosol, endosomes, lysosomes, or the nucleus gave information about their possible biological effects (120, 121), along with indications for the sake of designing of nanocarriers to achieve successful cell targeting and drug delivery. Targeting intracellular organelles or compartments with nanocarriers is widely used for diagnosis and therapy.

It is important to find out whether nanoparticles adhere to the exterior side of the plasma membrane or intracellular, in addition, to extricating the internalized nanoparticles (122–125). There is a definite indication that cellular uptake of nanoparticles is most commonly achieved by the endocytic pathway. Conversely, nanoparticles might be degraded, released, and delivered to new cells that will impact the activity of nanoparticles and cellular responses (126–128). It has been hypothesized that endocytosis of nanoparticle depends not only upon it but also on cell type (129), and for example, intestinal epithelial cells expose altered uptake processes in contrast to phagocytic cells such as macrophages (130).

Moreover, the organelle dysfunctions resulted in different human diseases as their functional activities are closely related to cellular growth, proliferation, differentiation, and cell death. Hence, the nanoparticle design for targeted delivery to the subcellular organelles is of remarkable consideration (131). For the development of optimized nanoparticles that can cross the barriers as well as give significant targeting, peer knowledge about the interface of nanoparticles with the cell and its organelles is required.

**Interaction with Mitochondria**

The intracellular targets for nanoparticles and therapeutic agents also include mitochondria for the identification, prevention, and treatment of different human diseases, for example, neurodegenerative diseases, cancer, ischemia-reperfusion injury, obesity, and diabetes, as mitochondria are essential for the fabrication of energy. Therefore, it can be utilized for site-specific delivery in tumor or neurodegenerative disease. The idea of the formulation of mitochondriotropic depended on carriers to deliver cargo either to protect the cell or to encourage cell death that has been studied by different researchers (132, 133).

Qu and his coworkers combined triphenylphosphonium (PPh3) to the surface of mesoporous silica nanoparticles loaded with doxorubicin (134). It was seen that the combination of delocalized cationic charge at surface ligand and three lipophilic phenyl groups enabled nanoparticle delivery across the mitochondrial membrane. These modified nanoparticles take about 8 h to release from liposomes and interact with mitochondria that led to a decline in levels of ATP in the cell, hence causing mitochondrial dysfunction, which leads to decrease cell feasibility up to 30% when exposed for 24 h _in vitro_. One of the crucial causes of neurodegenerative diseases, for example, Alzheimer’s disease, is mitochondrial dysfunction. Recently, Kwon _et al._ fabricated a cerium oxide nanoparticle–based delivery system that can overturn the onset of neuron damage by isolating inert oxygen species generated by improper functioning of mitochondria. It was concluded that cerium oxide nanoparticles which were functionalized with PPh3 and DSPE-PEG2000-methoxy could reuse oxygen atoms and limit further neuronal death _in vivo_. A method was reported by which small spherical gold nanoparticles were formulated to target the mitochondria (135). A recent method was designed for the preparation of polyoxometalate peptide-nanoparticle bioconjugates and the identification of their transport behaviors. The functionalization of the nanoparticle surfaces with peptides enables the significant trafficking of the nanoparticles to the mitochondria (137). Yamada _et al._ prepared a lipid derivative that is combined with a mitochondrial targeting signal peptide (MTS), which authorizes the targeted uptake of some protein types to mitochondria (138).

Jeena _et al._ synthesized novel peptide amphiphiles focusing on the mitochondrial targeting that was modified to ensure self-assembly upon gathering in mitochondria (139). The amphiphilic peptides comprising β-sheet develop blocks, conjugated to PPh3 in HeLa cells, observed to primarily accumulate in mitochondria, then resulted in fibrils because of high local concentration. This development of the fibrils disconcerted mitochondrial membranes forming the leaking of mitochondrial matters into the cytoplasm and consequent apoptosis. Forthcoming work utilizing this fabrication would necessitate targeted cell accuracy so as not to stimulate mitochondrial damage in normal healthy cells.

**Interaction with Endoplasmic Reticulum**

The proper folding and delivery of proteins can also be achieved by the endoplasmic reticulum (137). Furthermore, it is considered a critical site for loading of peptides into MHC primary histocompatibility complex class I molecules and following cytotoxic T cell responses (140). Thus, the endoplasmic reticulum promotes the proper functioning of the cell and its organelles. Cubillos-Ruiz _et al._ demonstrated exactly how endoplasmic reticulum stress in tumour-mediated dendritic cells endorses cancer growth and diminishes antitumor immunity (141). Estimation of an increment in endoplasmic reticulum stress factor, i.e., XBPI, was related to a shortened dendritic activity which also decreases T cell–dependent immunity. By using nanoparticles PEI (polyethylenimine), they were observed to enclosed definite siRNAs.

Moreover, the phagocytic dendritic cells were observed to engulf these nanosized complexes that encouraged approximately 65% gene silencing of XBPI. Silencing of endoplasmic reticulum stress in cancer-related dendritic cells employs intraperitoneal injections of the siRNA-PEI-based nanoparticles. The survival of mice was amplified with aggressive orthotopic ovarian cancers by the use of formulated nanoparticles. This innovative mechanism is responsible for the activation of cell-dependent antitumor immunity by the specific intracellular nanoparticle.

It was revealed by a time-course sampling of gold nanoparticles transported KDEL peptides were immediately confined to the endoplasmic reticulum in the first 5–15 min. In contrast, the majority of peptides were localized to the endoplasmic reticulum within 1 h (142). In this review, it is demonstrated that a delivery system for miR-29b employs PEI-capped gold nanoparticles targeting the endoplasmic reticulum to synergistically stimulate osteoblastic distinction (143).
**Interaction with Golgi Apparatus**

Golgi apparatus is one of the vital organelles for nanoparticle-based interventions. This cellular organelle is vital for the transport of post-translational amendments of freshly prepared proteins (144). Yu et al. worked on the pathological role of the Golgi apparatus to treat the tumor cells, which are defined as the abnormal growth of cells (145). For this achievement, both COX-2 inhibitor and Brefeldin A were encapsulated into PLGA-PEG nanoparticles. The COX-2 inhibitor such as celecoxib enclosed within the Golgi apparatus, whereas Brefeldin reserved protein delivery from the endoplasmic reticulum to the Golgi apparatus. The nanoparticle loading these two trivial molecules competently impaired the Golgi apparatus in 30 min of time course in vitro in murine metastatic breast tumor cells and displayed increased cytotoxicity. Besides, the combined transfer of these small molecules was detected to reduce the appearance of proteins related to metastasis.

Likewise, the experiments exposed that the Golgi apparatus did not employ the exocytosis in any of the verified cell lines. But, pharmacological inhibitors for microtubule formation and actin polymerization both repressed exocytosis, suggesting a purpose of both for the lysosomal delivery and cell membrane fusion (146). Fluorescent molecules, silica nanoparticles, and carbon quantum dots all were observed to target the Golgi apparatus which were decorated with t-cysteine. t-Cysteine-based chiral carbon quantum dots have the ability to target the Golgi apparatus (147).

**Interaction with the Nucleus**

By modifying the physicochemical properties of nanoparticles, the cellular organelle targeting can be achieved. For example, a size-dependent association for nanoparticle targeted to the nucleus for therapeutic interventions was observed by many researchers (148–150). The nucleus is a vital organelle to be targeted; its pores possessed a size range of 30 nm. It was observed that nanoparticles of large size labeled with particular nuclear localization order could reach the nucleus (151). Larger nanoparticles with a specific surface can access the nuclear content during mitosis when the nuclear membrane breaks down (152).

It was perceived that gold nanoparticles with a usual diameter of about 4 nm were capable of reaching the nucleus of breast cancer cells, despite the fact the nanoparticles with an average diameter of about 14 nm cannot enter the nuclear envelope and stayed dispersed all over the cell cytoplasm.

The targeting of the cell nucleus by nanoparticles has been described with two different pathways, including active transport of nanoparticles through the complex of nuclear membrane pore, which is assisted by nuclear localization signals (NLS). NLS is an amino acid sequence that “tags” a protein for import into the cell nucleus by nuclear transport. Remarkable examples of these NLS categorizations include small peptides that can be attached to cytoplasmic importins, for instance, importins α and β, that are situated in the perinuclear site (153). After fusing to cytoplasmic importins, nanoparticles with average diameters of 50 nm have been testified to cross the nucleus by adopting active transport by means of the nuclear pore complex (154). A second mechanism of nanoparticle access into the nucleus is achieved by passive diffusion of cytoplasmic nanoparticles via the open channel present in nuclear pore complex. These open channels vary in their diameter in the range of 6–9 nm (148,150,153,155). For adopting passive diffusion, the nanocarriers should be smaller enough to pass the nuclear pore. In recent research, it was reported that functionalized, positively charged, gold nanoparticles with a size range of 14 nm showed higher uptake as compared to particles with a size of 2 nm or 5 nm in diameter (156).

Huo and coworkers determined a size-dependent basis for nuclear uptake of gold nanoparticles in the breast cancer cell and observed that despite better cellular uptake for the larger nanoparticles, the 2-nm nanoparticles delivered DNA payloads to the nucleus 20× times more efficiently than their 14-nm counterparts (157). Nanoparticles with a calculated diameter of 2–6 nm were observed within the nucleus, whereas those larger than 10–16 nm were present outside the nucleus compartment. Based on that observation, the scientists tried to target triplex-forming oligonucleotides to the nucleus with the nanocarriers of 2 nm size which silenced the transcription factor c-myc promoter which is a promising target in anticancer therapy up to 50%. Some studies support the notion of size-dependent particle delivery to the nuclear membrane, as described for gold nanoparticles functionalized with PEG and polyarginine (107).

Tang et al. observed that nuclear delivery of quantum dots can be enhanced by covering them with NLS sequences at 20% density (158). Furthermore, it was confirmed that cellular and nuclear internalization was size-dependent using semiconductor quantum dot nanoparticles.

**Interaction with Lysosomes**

Lysosomes are considered oval or spherical or may be tubular intracellular vesicles with a pH of 4.5–5 (159). Their size is dependent on the cell type, which may vary between <1 mm and microns (160). The enzymatic degradation is their primary physiologic function moreover recycling of cellular compounds and other foreign molecules (161). Additionally, they are also involved in repairing of the plasma membrane, signaling, secretions, and processes of energy metabolism (162).

Although they are essential for eukaryotic cells, they are one of the main barriers for transcytosis of nanoparticles. Concerning the mainstream of the nanodelivery system, their ability is abbreviated as EEED (accessible entrance, diffusion, endocytosis, discharge). Thus, it was concluded that the endocytosis pathway is comparatively easier than exocytosis. When the nanoparticles are uptaken by the cell, the majority of the cells are subjected to an endolysosomal path that includes the delivery from early to late endosome their fate as maturation or fusion with lysosomes (163,164).

As the nanoparticles reach the acidic compartment of lysosomes, they get exposed to high ionic strength and various potent proteolytic enzymes can also interact with them (165). The nanoparticles get degraded in such a harsh environment which may also alter their colloidal stability. The enzymes also possess the ability to dissolve the outer polymer coating, which was done for improving their resilience. Kreiling et al. decorate radioactively labeled indium to gold nanoparticles with antibodies to lysosomal enzymes (166), which is then internalized by the cell. Once in the cell, the enzyme cleaves the antibodies, and the internalized nanoparticles are either destroyed or released into the extracellular space via diffusive transport (167).

**Interaction with Other Organelles**

In addition to the Golgi apparatus and lysosomes, there are other cellular organelles that are targeted by nanoparticles. For example, the mitochondria are targeted by nanoparticles that can deliver therapeutic agents to the mitochondrial matrix (168). These nanoparticles are designed to be smaller than 10 nm to pass through the mitochondrial outer membrane, which is a critical barrier for drug delivery (169). Moreover, the endoplasmic reticulum (ER) is another target for nanoparticles, which can be used to deliver drugs to the ER lumen (170). This targeting is achieved by attaching ligands that bind specifically to ER receptors (171).

These examples illustrate the versatility of nanoparticles in delivering therapeutic agents to specific cellular organelles. However, there are still many challenges to overcome in order to achieve effective and targeted drug delivery. For instance, the biodegradability of nanoparticles remains a concern, as their degradation products may accumulate in the body and cause adverse effects (172). Additionally, the toxicity of nanoparticles to the cell must be carefully considered, as nanoparticles may induce cellular stress and apoptosis (173).

In conclusion, nanoparticles are powerful tools for targeting and delivering therapeutic agents to specific cellular organelles. However, further research is needed to optimize their design and delivery mechanisms in order to achieve effective and safe drug delivery.
nanoparticles and observe in vitro delivery in endosome or lysosomes and how the polymeric coat shell gets separated from the inorganic gold nanoparticle. In vivo study of coated nanoparticles showed they were localized in liver cells. The polymeric coat was subjected to exocytosis, then undergoes renal filtration, resulting in urinary excretion (166).

It was also concluded that fluorescently labeled carboxylated polyvinyl alcohol gold nanoparticles may result in conformational alterations in intracellular lysosomal territories leading to aggregation of nanoparticles moreover appeasing of the fluorescence encodes located on the surface of polymer (167). Ma and colleagues fabricated nanoparticles of gold having various coatings such as coating with human γ-globulin (HGG), human serum albumin (HSA), or human serum fibrinogen (HSF). They examined their cytotoxicity when they get exposed to HeLa cells. It was observed that the rate of degradation of protein corona within the lysosomes is affected by the composition of the corona that also influences the aggregation and the cytotoxicity response of the nanoparticles (168). Besides, the lysosomal embedded metallic nanoparticle dissolution rate is considered they can reduce the concentration of intracellular nanoparticles moreover release of potentially toxic ions (169).

If the nanoparticles achieve the final destination of the eukaryotic cell and they cannot find any other escape, they either would fate by getting degraded by the action of enzymes or may be affected by the nature of the material and accumulated indefinitely. However, this is not applicable for internalization through epithelial cells of the small intestine which the first challenge to be crossed by the nanoparticles. For example, in a study, polystyrene nanoparticles with the concentration of about 500 mg/mL were subjected to caco-2 cells and incubated for 24 h, resulting in endolysosomal structures up to 2 mm in diameter as exposed by cLSM and TEM reports. Future work should be performed to reduce nanoparticle accumulation and degradation. It is needed to avoid the endolysosomal pathway altogether or get fused with the plasma membrane (8). Currently, a study on hemagglutinin-2 and/or metformin highlighted the potential endolysosomal escape and the resulting positive increase for exocytosis associated with increased transcytosis efficiency (170).

The co-delivery of molecules to the specific target utilizing an efficient nanoparticle is a new era in nanomedicine technologies. The studies shed light on most recent strategies adopted for intracellular organelle targeting of nanomedicine and highlight efficiency and effectiveness of nanocarrier trafficking to the specific intracellular organelle.

**CYTOTOXICITY OF NANOPARTICLES**

Nanoparticles have been used in cancer treatment and autoimmune disorders. However, cytotoxic effects of nanoparticles on organs and normal cells are a severely limiting factor that hinders their clinical uses. Moreover, the differences of nanoparticles size, particle shape, and surface area are main components that have a vital concusion on their therapeutic or unwanted actions.

The size of nanoparticles is dependent on the following parameters: surface-to-volume fraction (ratio), sedimentation velocity, attachment efficiency, mass diffusivity, and deposition velocity (171). However, the cytotoxicity of nanoparticles has been affected by changes in NP size (172). Nanoparticle size shows an essential interaction with the biological system (173). Ion release rates are affected by the size of nanoparticles; if the size of nanoparticles becomes smaller, it will lead to more interaction with the surface of the membrane, hence producing higher cytotoxic effects through penetration into the cell (174). Generally, cytotoxicity of nanoparticles that depends upon the size of nanoparticles also be correlated, the ability of nanoparticles to enter the biological system. Nanoparticle shapes also influence its toxicity. Nanoparticles are available in different shapes (e.g., filament, spherical, non-spherical, plate-shaped, and rod-like) (175). Internalization processes such as endocytosis and phagocytosis depend on the shapes of nanoparticles. Spherical nanoparticles show faster endocytosis than tubular nanoparticles (112). Non-spherical nanoparticles show more toxicity as they are vastly more exposed to blood flow (176).

Various biological aspects such absorption, plasma protein binding, colloidal behavior, and penetration over BBB are also affected by the surface charge presence on the nanoparticles (177). Negatively (−) charged nanoparticles show excellent absorption (through cellular mechanism) than positively (+) charged or neutral nanoparticles. Positively
charged nanoparticles cause platelet aggregation and hemolysis, resulting in cytotoxicity through plasma protein (178). The concentration of nanoparticles also affects on cytotoxicity; the toxicity changed with changing concentration (179). For example, the 2 mg/mL silicon concentration on cells had produced cytotoxic action, but in 4 mg/mL, there was no cytotoxic effect observed (180).

**Mechanism of Nanoparticle Toxicity**

The primary mechanism of nanoparticle toxicity is oxidative stress through the production of reactive O2 species, as illustrated in Fig. 3 (181). The surface properties of the nanoparticles affect many of the biological responses. Growth, adhesion, and different ions are the primary cellular responses. Nanoparticles produce oxidative stress (OS) through physicochemical interaction. So, the nanoparticles have ion, which causes toxicity in cell surface and can be oppressed to treat (remove) cancerous cell (182). The more interaction with the surface of the cell membrane and higher diameter of nanoparticles also increases the toxicity level of nanoparticles. Generally, the cell membrane is made up of the dynamic comprising protein and extracellular polymeric chain (183).

Toxicity is predominantly through an increase of reactive oxygen species (ROS) levels in the cell, as nanoparticles enter the cell through endocytosis. Inflammatory factors such as tumor necrosis factor (TNF-α), II-6, II-8, and II-1 can also be increased by nanoparticles and finally cause mitochondrial damage (184–186). Mitochondria, endoplasmic reticulum, peroxisome, and microsomes are the essential component of intracellular organelles (ROS) in the cell membrane (187,188). Through the mitochondrial electron transport system, an intrinsic source of reactive oxygen species in mitochondria (20). With increased accumulation of calcium (Ca2+) in the cytoplasm, there will be activation of the mitochondrial electron transport chain and ROS generation occurs. Adenosine triphosphate (ATP) water and a small concentration of O2 are produced during the synthesis of mitochondria, resulting in the early stages of ROS

**Fig. 4.** Mechanisms underlying NP cytotoxicity [196]
production. Superoxide anion, the first reactive oxygen element that is produced by complex I (NADH ubiquinone oxidoreductase) and complex III (co-enzyme Q, bc1 complex, and ubiquinone/cytochrome c reductase) activity in the mitochondrial matrix and intermembrane space, is generated by mitochondria, respectively (189,190). Copper and manganese are those metals that catalyze the conversion of superoxide anions into hydrogen peroxide (191). Alpha ketoglutarate dehydrogenase and monoamine oxidase (MAO) are important sources of reactive oxygen species (ROS) (192,193). Many biological functions have been modulated by nanoparticle-induced ROS. Nanomaterial concentration is correlated with the occurrence of reactive oxygen species (ROS) and oxidative stress to which cell is exposed (173). Oxidative stress causes non-toxicity, as in alteration to cell motility, cytotoxicity, unregulated cell signaling, DNA damage, apoptosis, and cancer proliferation (194,195).

The mechanisms of nanoparticle (NP) toxicity is demonstrated in Fig. 4 and discussed briefly as:

a) With an increase of reactive O2 species (ROS), nanoparticles may cause oxidation.
b) Through the perforation process, nanoparticles may damage cell membranes.
c) Nanoparticles, through interfering cellular ion transport and inhibited cell division, cause damage to the components of the cytoskeleton.
d) Nanoparticles damage DNA and process of protein synthesis, thus producing mutagenesis.
e) Cell energy imbalance occurs by mitochondrial damage and by interfering metabolism of mitochondria through nanoparticles.
f) Nanoparticles also interfere with the formation of lysosomes, triggering the apoptosis, autophagy, and degradation of macromolecules.
g) Altered transport of substances in and out of cell and structure changes in membranes and proteins is also caused by nanoparticles.
h) Nanoparticles cause disturbance of the standard mechanism of cell metabolism and organ and tissue metabolism through activation and synthesis of inflammatory mediators.

**Nanoparticle Cytotoxicity Assessment Method**

Cytotoxicity of nanoparticles can be assessed through different methods. Nanoparticle types, experimental models, and unwanted effects imposed by nanocarriers are shown in Fig. 5.

**In Vitro Assessment Assay**

*In vitro* assessment method is further divided into the following assay: proliferation, apoptosis, necrosis, and OS assays. The proliferation assay measures cellular metabolism through the assessment of metabolically active cells, whereas apoptosis assessment is carried out by different assays including Annexin-V assay, Comet assay, TUNEL assay, and inspection of morphological changes (197,198).

The integrity of the membrane is measured by the necrosis assay. It is also used to determine the viability of the cells. Neutral Red and Trypan Blue are commonly used dyes for membrane integrity measurement (199). The production of reactive ROS and reactive nitrogen species (RNS) lead after exposure of nanoparticles (200). 2',7'-
Table II. Different Assays and Dyes Used for Assessment of Nanoparticle Toxicity

| Assay name | Dye used | Cell lines | advantages | Cytotoxic effects | Reference |
|------------|----------|------------|------------|------------------|-----------|
| (1) Proliferation assays | (1) 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is the most commonly used tetrazolium salt | Rat hippocampal neurons | (1) Results easily, reproducible (2) Minimum model cell manipulation | Avoided due to high toxicity | (203–206) |
| (2) Apoptosis assay | (2) Alamar Blue Annexin-v and propidium iodide | Rat hepatocyte Human HepG2 hepatoma cells | Detection of mutagenicity Used to assess the toxicity of zinc oxide nanoparticles Detection of toxicity imposed by silicon dioxide nanoparticles | | (197,207) (206) (198,208) (209) |
| (b) Comet assay | *Dunaliella tertiolecta* | | Detection of toxicity imposed by silicon dioxide nanoparticles | Selenium nanoparticle toxicity | (210) |
| (c) TUNEL assay | | Goto Kakizaki rats (pancreatic beta cell) | Measured integrity of the membrane find cell viability Maintains membrane stability | | (209) (211) (212,213) (202) (214) |
| (3) Necrotic assay | (a) Neutral red (2-aminomethyl-7-dimethylaminozenomiumchloride) | Lysosomes | Detected by flow cytometry | | (209) |
| (b) Trypan Blue | | MDCK kidney cells | | | (211) (212,213) |
| (4) Oxidative stress | 2′,7′-Dichlorofluorescein diacetate (DCFDA) | Pcl2 cell (rat adrenal medulla) | | | (202) (214) |

Dichlorofluorescein diacetate (DCFDA) is a non-fluorescent probe. It is reactive to HO, RO, and ROO in the presence of cellular peroxidases (201). Lipid peroxidation assay is also used for the assessment of oxidative stress (202). In Table II, we elaborate the discussion on the toxicity imposed by the nanoparticles on rat, mouse, pig, guinea pig, human cell lines, and human.

**In Vivo Toxicity**

Animal models, such as rats and mice, are used for in vivo toxicity. The parameters, such as hematology, absorption, and metabolism, are assessed by the in vivo method. The route of localization of nanoparticles to the tissue or organ is examined through biodistribution studies. Radiolabels are used to detect the nanoparticles in the dead and live animals (215). After exposure, the clearance of NP has been done through examination of biotransformation or elimination of nanoparticles at a different time interval (216). Another method of toxicity assessment of nanoparticles is the examination difference in the chemistry of serum and type of cell after exposure to nanoparticles (217). The cytotoxicity level caused by a nanoparticle is measured through histopathology of the cell (218). Tissues such as lungs, heart, and others that exposed to nanoparticles are used for histopathology examination (219,220).

**CONCLUSION**

In this review, we presented a detailed overview about internalization of nanoparticles, interaction with intracellular organelles and their cytotoxicity, and also different methods used for the assessment of their toxicity. The internalization of nanoparticles can be achieved by crossing intestinal barriers such as the mucus layer, the epithelial layer, and tight junctions. The physical and chemical properties of nanoparticles also affect their internalization, and the fate of these particles after their cellular uptake at the cellular and subcellular levels is an extensive study. The small size and the relatively large surface area of NPs resulted in increased toxicity when compared to particles in micrometer size. For obtaining an optimized nanodelivery system, their cellular-induced cytotoxic response should also be adequately studied. Nanoparticles have been used in cancer treatment and autoimmune disorders. However, we conclude that the cytotoxicity of nanoparticles has been affected by changes in NP size. Nanoparticle size shows an essential interaction with barriers such as the mucus layer, the epithelial layer, and tight junctions. The physical and chemical properties of nanoparticles also affect their internalization, and the fate of these particles after their cellular uptake at the cellular and subcellular levels is an extensive study. The small size and the relatively large surface area of NPs resulted in increased toxicity when compared to particles in micrometer size. For obtaining an optimized nanodelivery system, their cellular-induced cytotoxic response should also be adequately studied. Nanoparticles have been used in cancer treatment and autoimmune disorders. However, we conclude that the cytotoxicity of nanoparticles has been affected by changes in NP size. Nanoparticle size shows an essential interaction with biological system. The ion release rate is affected by the size of nanoparticles; if the size of nanoparticles becomes smaller, it will lead to more interaction with the surface of the membrane, hence producing higher cytotoxic effects through penetration into the cell. Generally, cytotoxicity of nanoparticles that depends upon the size of nanoparticles also be correlated, the ability of nanoparticles to enter the biological system.

We also conclude that the shapes of nanoparticles also influence their toxicity. Nanoparticles are available in different shapes (e.g., filament, spherical, non-spherical, plate-shaped, and rod-like). Internalization processes such as endocytosis and phagocytosis depend on the shapes of nanoparticles. Spherical nanoparticles show faster endocytosis and phagocytosis than a tubular nanoparticle. In future, the availability of NPs has opened up new technology in the medical field. The distinctive properties of nanomaterials give them many areas of human benefit, including catalysis, medicines, antimicrobials, biosensors, drug delivery, and electronics. Nanoparticles may be attached to the surface of biological membranes by adsorption or electrostatic interactions, and damage the cells...
by producing reactive oxygen species, leading to protein denaturation, lipid peroxidation, DNA damage, and ultimately cell death.

REFERENCES

1. Lipp R. Major advances in oral drug delivery over the past 15 years. Am Pharm Rev. 2013;16:28–35.
2. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557–70.
3. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv. 2015;12(9):1459–73.
4. Hunter AC, et al. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiologic perspective. Maturitas. 2012;73(1):5–18.
5. Pawar VK, et al. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J Control Release. 2014;186:168–83.
6. Malingré MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest New Drugs. 2001;19(2):155–62.
7. Mei L, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2015;65(6):880–90.
8. Reinholz J, Landfester K, Mailänder V. The challenges of oral drug delivery via nanocarriers. Drug Deliv. 2018;25(1):1694–705.
9. Bobo D, et al. Nanoparticle-based medicines: a review of FDA-approved medicines and clinical trials to date. Pharm Res. 2016;33(10):2373–87.
10. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10–29.
11. Hackett JT, Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus. Adv Drug Deliv Rev. 2018;124:125–39.
12. Chen M-C, et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32(36):9826–38.
13. Banerjee A, et al. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release. 2016;238:176–85.
14. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289.
15. Kumar S, et al. Shape and size-dependent immune response to antigen-carrying nanoparticles. J Control Release. 2015;220:141–8.
16. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release. 2007;121(1-2):3–9.
17. Gerloff K, et al. Cytoxicity and oxidative DNA damage by nanoparticles in human intestinal Caco-2 cells. Nanotoxicology. 2009;3(4):355–64.
18. Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol. 2008;22(3):391–409.
19. Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12(11):958.
20. Pelaseyed T, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260(1):8–20.
21. Johansson ME, et al. Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci. 2011;68(22):3635.
22. Corfield AP. Mucins: a biologically relevant glycan barrier in mucusal protection. Biochimica et Biophysica Acta (BBA)-General Subjects. 2015;1850(1):236–52.
23. Jonckheere N, et al. Membrane-bound mucin modular domains: from structure to function. Biochimie. 2013;95(6):1077–86.
Artursson P, Knight SD. Breaking the intestinal barrier to deliver drugs. Science. 2015;347(6223):716–7.

Turner JR et al. The role of molecular remodeling in differential regulation of tight junction permeability. In Seminars in cell & developmental biology. 2014. Elsevier.

Barnes W, J D, Schultke, and M Fromm. Claudin-related intestinal diseases. In Seminars in cell & developmental biology. 2015. Elsevier.

Mirsny RJ, et al. A key claudin extracellular loop domain is critical for epithelial barrier integrity. Am J Pathol. 2008;172(4):905–15.

Sun H, et al. Crystal structure of a claudin provides insight into the architecture of tight junctions. Science. 2014;344(6181):304–7.

Aguirre TA, et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016;106:223–41.

Maher S, et al. Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. Eur J Pharm Sci. 2009;38(4):291–300.

Taverner A, et al. Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J Control Release. 2015;210:189–97.

Chettimada S, et al. Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest. 2005;115(10):2702–15.

Chayborough DR, et al. Epithelial myosin light chain kinase–dependent barrier dysfunction mediates T cell activation–induced diarrhea in vivo. J Control Release. 2005;115(10):2702–9.

Zhang L, et al. Designing nanoparticles with improved tumor penetration: surface properties from the molecular architecture viewpoint. J Mater Chem B. 2019;7(6):953–64.

Becker M., An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. 2005.

Liu X, et al. Numerical study of clathrin-mediated endocytosis of nanoparticles by cells under tension. Acta Mech Sinica. 2019;35(3):691–701.

Mikulčič S, Florin L. The endocytic trafficking pathway of oncogenic papillomaviruses. Papillomavirus Res. 2019;7:135–7.

Sahay G, Alakova DY, Kabanov AV. Endocytosis of nanoparticles. J Control Release. 2018;267:166–79.

Chatterjee A, et al. Enhanced paracellular transport facilitates delivery of poly (ε-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J Pharm Sci. 2019;98(6):2940–50.

Anselmo AC, et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. ACS Nano. 2015;9(3):3169–77.

Guo P, et al. Nanoparticle elasticity directs tumor uptake. Nat Commun. 2018;9(1):130.

Mei L, Sun H, Song C. Local delivery of modified paclitaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J Pharm Sci. 2019;98(6):2940–50.
120. Muhlfeld C, et al. The role of surface charge in cellular uptake and phagocytosis. Nat Rev Immunol. 2012;12(7):492.
121. Foster R, et al. Size-dependent endocytosis of nanoparticles. Adv Mater. 2009;21(4):149–24.
122. Oh E, et al. Cellular uptake and fate of PEGylated gold nanoparticles is dependent on both cell-penetration peptides and particle size. ACS Nano. 2011;5(8):6344–48.
123. Hirota K, et al. Optimum conditions for efficient phagocytosis of rifampin-loaded PLGA microspheres by alveolar macrophages. J Control Release. 2007;119(1):69–76.
124. Swiston AJ, et al. Freely suspended cellular “backpacks” lead to cell aggregate self-assembly. Biomacromolecules. 2010;11(7):1826–32.
125. Stoehr LC, et al. Shape matters: effects of silver nanospheres and wires on human alveolar epithelial cells. Part Fibre Toxicol. 2011;8(1):36.
126. Ahmed KBR, et al. Mitochondrial changes and wires on human alveolar epithelial cells. Part Fibre Toxicol. 2011;8(1):36.
127. Champion JA, Mitragotri S. Role of target geometry in and particle size. ACS Nano. 2011;5(8):6344–48.
128. Fowler R, et al. Nanoparticle transport in epithelial cells: an overview about state-of-the-art techniques and their limitations. Nanomedicine. 2014;9(12):1885–96.
129. Yang C, et al. Mitophagy induced by nanoparticle–peptide conjugates enabling an alternative intracellular trafficking route. Biomaterials. 2015;65:56–65.
130. Yamada Y, Harashima H. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier. Mitochondrion. 2013;13(5):526–32.
131. Jeena M, et al. Mitochondria localization induced self-assembly of peptide amphiphiles for cellular dysfunction. Nat Comm. 2017;8(1):26.
132. Mukai Y, et al. Induction of endoplasmic reticulum–endosome fusion for antigen cross-presentation induced by poly(γ-glutamic acid) nanoparticles. J Immunol. 2011;187(12):6249–55.
133. Cubillos-Ruiz JR, et al. ER stress sensor XBPI controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527–38.
134. Wang G, et al. KDEL peptide gold nanoconstructs: promising nanoplanforms for drug delivery. Nanomedicine. 2013;9(3):366–74.
135. Pan T, et al. miR-29b-loaded gold nanoparticles targeting to the endoplasmic reticulum for synergistic promotion of osteogenic differentiation. ACS Appl Mater Interfaces. 2016;8(30):19217–27.
136. Rodrigues J, Banks P, Lydall D. Vps74 connects the Golgi apparatus to the mitochrondia using mesoporous silica nanoparticle conjugated monodisperse mesoporous silica nanoparticles. J Gene Med. 2012;14(9-10):580–9.
137. Yang C, et al. Peptide modified gold nanoparticles for improved cellular uptake, nuclear transport, and intracellular retention. Nanoscale. 2014;6(20):12026–35.
208. Schiavo S, et al. Genotoxic and cytotoxic effects of ZnO nanoparticles for Dunaliella tertiolecta and comparison with SiO2 and TiO2 effects at population growth inhibition levels. Sci Total Environ. 2016;550:619–27.

209. Singh AP, et al. Developments in encapsulation of insulin: is oral delivery now possible? J Pharm Biopharm Res. 2019;1(1):74–93.

210. Mo Y, Lim L-Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release. 2005;108(2-3):244–62.

211. Bitensky L. The reversible activation of lysosomes in normal cells and the effects of pathological conditions. in Ciba Foundation Symposium-Anterior Pituitary Secretion (Book I of Colloquia on Endocrinology). 1963. Wiley Online Library.

212. Huang M, Khor E, Lim L-Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004;21(2):344–53.

213. Kononenko V, et al. Comparative in vitro genotoxicity study of ZnO nanoparticles, ZnO macroparticles and ZnCl2 to MDCK kidney cells: size matters. Toxicol in Vitro. 2017;40:256–63.

214. Hussain SM, et al. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci. 2006;92(2):456–63.

215. Kim SC, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72(1-3):191–202.

216. Li Y-P, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001;71(2):203–11.

217. Lei R, et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. Toxicol Appl Pharmacol. 2008;232(2):292–301.

218. Baker GL, et al. Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles. Toxicol Sci. 2007;101(1):122–31.

219. Zhu M-T, et al. Comparative study of pulmonary responses to nano-and submicron-sized ferric oxide in rats. Toxicology. 2008;247(2-3):102–11.

220. Kumar V, Sharma N, Maitra S. In vitro and in vivo toxicity assessment of nanoparticles. Int Nano Lett. 2017;7(4):243–56.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.